Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy

2017 ◽  
Vol 75 ◽  
pp. 308-309 ◽  
Author(s):  
P. Pradere ◽  
J.M. Michot ◽  
S. Champiat ◽  
F.X. Danlos ◽  
A. Marabelle ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Antibody Therapy ◽  
Monoclonal Antibody Therapy ◽  
Pulmonary Aspergillosis ◽  
Cell Death Protein

scholarly journals Protective Activity of Programmed Cell Death Protein 1 Blockade and Synergy With Caspofungin in a Murine Invasive Pulmonary Aspergillosis Model

2020 ◽  
Vol 222 (6) ◽  
pp. 989-994 ◽  
Author(s):  
Sebastian Wurster ◽  
Prema Robinson ◽  
Nathaniel D Albert ◽  
Jeffrey J Tarrand ◽  
Marisa Goff ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Combined Treatment ◽  
Invasive Pulmonary Aspergillosis ◽  
Immune Checkpoint Blockade ◽  
Pulmonary Aspergillosis ◽  
Leukocyte Accumulation ◽  
Significant Survival ◽  
Checkpoint Inhibitor Therapy ◽  
Cell Death Protein

Abstract Pharmacological immune checkpoint blockade has revolutionized oncological therapies, and its remarkable success has sparked interest in expanding checkpoint inhibitor therapy in infectious diseases. Herein, we evaluated the efficacy of programmed cell death protein 1 (PD-1) blockade in a murine invasive pulmonary aspergillosis model. We found that, compared with isotype-treated infected control mice, anti–PD-1–treated mice had improved survival, reduced fungal burden, increased lung concentrations of proinflammatory cytokines and neutrophil-attracting chemokines, and enhanced pulmonary leukocyte accumulation. Furthermore, combined treatment with anti–PD-1 and caspofungin resulted in a significant survival benefit compared with caspofungin or anti–PD-1 therapy alone, indicating a synergistic effect between PD-1 inhibitors and immunomodulatory antifungal agents.

Update on Targeted Therapy—Focus on Monoclonal Antibodies

2008 ◽  
Vol 21 (1) ◽  
pp. 4-16 ◽  
Author(s):  
Meredith B. Toma ◽  
Patrick J. Medina
Keyword(s):  
Monoclonal Antibody ◽  
Cell Death ◽  
Monoclonal Antibodies ◽  
Targeted Therapy ◽  
Antibody Therapy ◽  
Therapeutic Agents ◽  
Monoclonal Antibody Therapy ◽  
Effective Management ◽  
Cellular Targets ◽  
Common Structure

Monoclonal antibodies represent a diverse class of therapeutic agents frequently used in the treatment of various malignancies. Monoclonal antibodies have a common structure with varying amounts of human and nonhuman components. These agents have been developed to identify and to interact with specific cellular targets or signaling pathways, leading to cell death by various mechanisms. Adverse effects associated with monoclonal antibodies are related to their structure (human vs nonhuman content) and to their cellular targets. Pharmacists should be familiar with this class of therapeutic agents to provide effective management and to monitor patients receiving monoclonal antibody therapy.

Sign in / Sign up

Export Citation Format

Share Document